Effects of Itopride Hydrochloride on Plasma Gut-Regulatory Peptide and Stress-Related Hormone Levels in Healthy Human Subjects

  title={Effects of Itopride Hydrochloride on Plasma Gut-Regulatory Peptide and Stress-Related Hormone Levels in Healthy Human Subjects},
  author={Fumihiko Katagiri and Toru Shiga and Shin Inoue and Yuhki Sato and Hiroki Itoh and Masaharu Takeyama},
  pages={115 - 121}
Itopride hydrochloride (itopride), a gastrokinetic drug, has recently been evaluated for its clinical usefulness in functional dyspepsia. We investigated effects of itopride on human plasma gastrin-, somatostatin-, motilin-, and cholecystokinin (CCK)-like immunoreactive substances (IS); adrenocorticotropic hormone (ACTH)-immunoreactive substances (IS), and cortisol under stress conditions in healthy subjects. A single administration of itopride caused significant increases in plasma… 

Figures and Tables from this paper

The Role of GI Peptides in Functional Dyspepsia and Gastroparesis: A Systematic Review

Serotonin agonists have a potential to improve symptoms in both FD and idiopathic gastroparesis and drugs acting on the GLP-1 and on the PYY receptors deserve further investigation.

A double‐blind, randomized, placebo‐controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers

In healthy subjects, itopride reduced total PP gastric volume without accelerating gastric emptying or significantly altering gastric motor and sensory function in healthy individuals.

Prokinetic Agents

Prucalopride, a highly selective 5-HT4 receptor agonist, is used primarily to treat chronic constipation and pseudo-obstruction.

Transient Gastric Irritation in the Neonatal Rats Leads to Changes in Hypothalamic CRF Expression, Depression- and Anxiety-Like Behavior as Adults

The present results suggest that transient gastric irritation in the neonatal period can induce a long lasting increase in depression- and anxiety-like behaviors, increased expression of CRF in the hypothalamus, and an increased sensitivity of HPA axis to stress.

Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers

At steady state, once-daily itopride ER at 150 mg has a bioavailability comparable with that of itoprise IR at 50 mg given three times a day under fasting conditions, which is generally well tolerated.

Recent insights into digestive motility in functional dyspepsia

There is growing interest in alterations in gastric motility, such as accommodation to a meal or gastric emptying, and visceral sensation in FD, with special attention given to digestive dysmotility.

Development of a physiologically based pharmacokinetic model to predict the effects of flavin‐containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure

A meta-analysis of relative enzyme activities suggested that F MO3 activity in subjects with homozygous Glu158Lys and Glu308Gly mutations is ~47% lower than those carrying two wild-type FMO3 alleles, which suggested that for FMO 3 metabolised drugs with a safety margin of 2 or more, proactive genotyping FMO2 may not be necessary.



Comparison of the effects of cytoprotective drugs on human plasma adrenocorticotropic hormone and cortisol levels with continual stress exposure.

The effects of cetraxate, ecabet and sulpiride on the plasma levels of ACTH and cortisol under stress conditions by repetitive blood sampling suggest that ecabet may have a modulatory effect on the HPA axis while sulpirides may be beneficial in stress-related disease.

Clinical application of an enzyme immunoassay for cholecystokinin‐like immunoreactive substance for determination of the human plasma levels: the effect of metoclopramide on gastrointestinal peptides and stress‐related hormones

It is hypothesized that metoclopramide might have an accelerating gastric‐emptying effect and a modulatory effect on the hypothalamo‐pituitary‐adrenal (HPA) axis and the autonomic nervous function and these effects might be beneficial in stress‐related diseases, which suggest that this medicine has clinicopharmacological activities.

Ecabet sodium raises plasma levels of calcitonin gene‐related peptide and substance P in healthy humans

It is hypothesized that ecabet might stimulate capsaicin‐sensitive afferent nerves indirectly and improve mucosal blood flow; this might be a key mechanism underlying its gastroprotective action.

Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome

Human intestinal motility is probably modulated by exogenous CRH, and the brain-gut in IBS patients may have an exaggerated response to CRH.

Effects of mosapride citrate on human plasma levels of motilin, gastrin, somatostatin, and secretin.

The results suggest that the pharmacological effects of mosapride on gastrointestinal functions are closely related to changes in motilin-immunoreactive substance levels in human plasma.

Stimulatory Action of Itopride Hydrochloride on Colonic Motor Activity in Vitro and in Vivo

Itopride has a stimulatory action on colonic peristalsis, propelling colonic luminal contents, different from that of cisapride and mosapride, therefore, itopride may be a useful drug for the treatment of functional bowel disorders such as functional constipation.

Hange-shashin-to raises levels of somatostatin, motilin, and gastrin in the plasma of healthy subjects.

Changes in hormone levels (somatostatin, motilin, and gastrin) might relate to normalization of the upper and lower gastrointestinal system by Hange-shashin-to.

Ranitidine Increases Bioavailability of Acetaminophen by Inhibiting First‐Pass Glucuronidation in Man

The effects of ranitidine are as a result of the prevention of first-pass hepatic metabolism, by prevention of acetaminophen glucuronyltransferase, and care must be taken whenacetaminophen and ranitidine are coadministered.

Cholecystokinin antagonists: Pharmacological and therapeutic potential

  • R. Herranz
  • Biology, Medicine
    Medicinal research reviews
  • 2003
A broad assortment of potent and selective CCK1 and CCK2 antagonists of diverse chemical structure are provided through optimization programs of lead compounds designed based on the structures of the C‐terminal tetrapeptide, CCK‐4, or the non‐peptide natural compound, asperlicin, or derived from random screening programs.